0HA3.L - Adverum Biotechnologies, Inc.
| Previous close | 1.1700 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,426 |
| Market cap | 914,897 |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
After losing 12% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain
Key Insights Given the large stake in the stock by institutions, Adverum Biotechnologies' stock price might be...
- Zacks
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
- Simply Wall St.
Here's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Zacks
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
- Simply Wall St.
Quite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
- Zacks
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.
